A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 05 02 2021
accepted: 21 04 2021
revised: 20 04 2021
pubmed: 5 5 2021
medline: 5 11 2021
entrez: 4 5 2021
Statut: ppublish

Résumé

As atrophy represents the most relevant driver of progression in multiple sclerosis (MS), we investigated the impact of different patterns of brain and spinal cord atrophy on disability worsening in MS. We acquired clinical and MRI data from 90 patients with relapsing-remitting MS and 24 healthy controls (HC). Clinical progression at follow-up (mean 3.7 years) was defined according to the Expanded Disability Status Scale-Plus. Brain and spinal cord volumes were computed on MRI brain scans. After normalizing each participants' brain and spine volume to the mean of the HC, z-score cut-offs were applied to separate pathologically atrophic from normal brain and spine volumes (accepting a 2.5% error probability). Accordingly, MS patients were classified into four groups (Group I: no brain or spinal cord atrophy N = 40, Group II: brain atrophy/no spinal cord atrophy N = 11, Group III: no brain atrophy/ spinal cord atrophy N = 32, Group IV: both brain and spinal cord atrophy N = 7). All patients' groups showed significantly lower brain volume than HC (p < 0.0001). Group III and IV showed lower spine volume than HC (p < 0.0001 for both). Higher brain lesion load was identified in Group II (p = 0.049) and Group IV (p = 0.023) vs Group I, and in Group IV (p = 0.048) vs Group III. Spinal cord atrophy (OR = 3.75, p = 0.018) and brain + spinal cord atrophy (OR = 5.71, p = 0.046) were significant predictors of disability progression. The presence of concomitant brain and spinal cord atrophy is the strongest correlate of progression over time. Isolated spinal cord atrophy exerts a similar effect, confirming the leading role of spinal cord atrophy in the determination of motor disability.

Identifiants

pubmed: 33942160
doi: 10.1007/s00415-021-10576-9
pii: 10.1007/s00415-021-10576-9
pmc: PMC8563557
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4698-4706

Informations de copyright

© 2021. The Author(s).

Références

Yalachkov Y, Soydaş D, Bergmann J et al (2019) Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord 30:33–37. https://doi.org/10.1016/j.msard.2019.01.049
doi: 10.1016/j.msard.2019.01.049 pubmed: 30735970
Asch P van (2011) Impact of mobility impairment in multiple sclerosis two - patients’ perspectives. Eur Neurol Rev 6:115–120. https://doi.org/10.17925/ENR.2011.06.02.115
Barkhof F (2002) The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 15:239–245. https://doi.org/10.1097/00019052-200206000-00003
doi: 10.1097/00019052-200206000-00003 pubmed: 12045719
Bester M, Petracca M, Inglese M (2014) Neuroimaging of multiple sclerosis, acute disseminated encephalomyelitis, and other demyelinating diseases. Semin Roentgenol 49:76–85. https://doi.org/10.1053/j.ro.2013.09.002
doi: 10.1053/j.ro.2013.09.002 pubmed: 24342677
Minneboo A, Jasperse B, Barkhof F et al (2007) Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. J Neurol Neurosurg Psychiatry 79:917–924. https://doi.org/10.1136/jnnp.2007.124123
doi: 10.1136/jnnp.2007.124123 pubmed: 18077480
Popescu V, Agosta F, Hulst HE et al (2013) Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 84:1082–1091. https://doi.org/10.1136/jnnp-2012-304094
doi: 10.1136/jnnp-2012-304094 pubmed: 23524331
Daams M, Steenwijk MD, Wattjes MP et al (2015) Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis. Neurology 85:248–255. https://doi.org/10.1212/WNL.0000000000001756
doi: 10.1212/WNL.0000000000001756 pubmed: 26115736
Rocca M, a, Horsfield M a, Sala S, et al (2011) A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. Neurology 76:2096–2102. https://doi.org/10.1212/WNL.0b013e31821f46b8
doi: 10.1212/WNL.0b013e31821f46b8 pubmed: 21670439
Daams M, Weiler F, Steenwijk MD et al (2014) Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: Relation to brain findings and clinical disability. Mult Scler J 20:1860–1865. https://doi.org/10.1177/1352458514533399
doi: 10.1177/1352458514533399
Biberacher V, Boucard CC, Schmidt P et al (2015) Atrophy and structural variability of the upper cervical cord in early multiple sclerosis. Mult Scler 21:875–884. https://doi.org/10.1177/1352458514546514
doi: 10.1177/1352458514546514 pubmed: 25139943
Zeydan B, Gu X, Atkinson EJ et al (2018) Cervical spinal cord atrophy. Neurol Neuroimmunol Neuroinflamm 5:e435. https://doi.org/10.1212/NXI.0000000000000435
doi: 10.1212/NXI.0000000000000435 pubmed: 29435472 pmcid: 5795903
Tsagkas C, Magon S, Gaetano L et al (2018) Spinal cord volume loss. Neurology 91:e349–e358. https://doi.org/10.1212/WNL.0000000000005853
doi: 10.1212/WNL.0000000000005853 pubmed: 29950437
Ruggieri S, Petracca M, Miller A et al (2015) Association of deep gray matter damage with cortical and spinal cord degeneration in primary progressive multiple sclerosis. JAMA Neurol 72:1–9. https://doi.org/10.1001/jamaneurol.2015.1897
doi: 10.1001/jamaneurol.2015.1897
Oh J, Sotirchos ES, Saidha S et al (2015) Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis. Neurology. https://doi.org/10.1212/WNL.0000000000001257
doi: 10.1212/WNL.0000000000001257 pubmed: 26718574 pmcid: 4653105
Sastre-Garriga J, Pareto D, Battaglini M et al (2020) MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol 16:171–182. https://doi.org/10.1038/s41582-020-0314-x
doi: 10.1038/s41582-020-0314-x pubmed: 32094485 pmcid: 7054210
Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302. https://doi.org/10.1002/ana.22366
doi: 10.1002/ana.22366 pubmed: 21387374 pmcid: 3084507
Lublin FD, Reingold SC, Cohen J, a, et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:278–286. https://doi.org/10.1212/WNL.0000000000000560
doi: 10.1212/WNL.0000000000000560 pubmed: 24871874 pmcid: 4117366
Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://doi.org/10.1016/S1474-4422(17)30470-2
doi: 10.1016/S1474-4422(17)30470-2 pubmed: 29275977
Smith SM (2002) Fast robust automated brain extraction. Hum Brain Mapp 17:143–155. https://doi.org/10.1002/hbm.10062
doi: 10.1002/hbm.10062 pubmed: 12391568 pmcid: 6871816
Battaglini M, Jenkinson M, De Stefano N (2012) Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp 33:2062–2071. https://doi.org/10.1002/hbm.21344
doi: 10.1002/hbm.21344 pubmed: 21882300
Healy BC, Arora A, Hayden DL et al (2012) Approaches to normalization of spinal cord volume: Application to multiple sclerosis. J Neuroimaging 22:e12–e19. https://doi.org/10.1111/j.1552-6569.2011.00629.x
doi: 10.1111/j.1552-6569.2011.00629.x pubmed: 21854479
Raji A, Ostwaldt A-C, Opfer R et al (2018) MRI-based brain volumetry at a single time point complements clinical evaluation of patients with multiple sclerosis in an outpatient setting. Front Neurol. https://doi.org/10.3389/fneur.2018.00545
doi: 10.3389/fneur.2018.00545 pubmed: 30140245 pmcid: 6095003
Rio J, Nos C, Tintorè M et al (2006) Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59:344–352. https://doi.org/10.1002/ana.20740
doi: 10.1002/ana.20740 pubmed: 16437558
Kragt JJ, Van Der Linden F, Nielsen JM et al (2006) Clinical impact of 20% worsening on timed 25-foot walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 12:594–598. https://doi.org/10.1177/1352458506070768
doi: 10.1177/1352458506070768 pubmed: 17086905
Cadavid D, Cohen JA, Freedman MS et al (2017) The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler 23:94–105. https://doi.org/10.1177/1352458516638941
doi: 10.1177/1352458516638941 pubmed: 27003945
Rocca MA, Comi G, Filippi M (2017) The role of T1-weighted derived measures of neurodegeneration for assessing disability progression in multiple sclerosis. Front Neurol. https://doi.org/10.3389/fneur.2017.00433
doi: 10.3389/fneur.2017.00433 pubmed: 28928705 pmcid: 5591328
Zivadinov R, Banas a C, Yella V, et al (2008) Comparison of three different methods for measurement of cervical cord atrophy in multiple sclerosis. AJNR Am J Neuroradiol 29:319–325. https://doi.org/10.3174/ajnr.A0813
doi: 10.3174/ajnr.A0813 pubmed: 17974604 pmcid: 8118969
Lukas C, Sombekke MH, Bellenberg B et al (2013) Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology 269:542–552. https://doi.org/10.1148/radiol.13122566
doi: 10.1148/radiol.13122566 pubmed: 23737540
Furby J, Hayton T, Altmann D et al (2010) A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol 257:1508–1516. https://doi.org/10.1007/s00415-010-5563-y
doi: 10.1007/s00415-010-5563-y pubmed: 20437181
Kearney H, Rocca M, a, Valsasina P, et al (2014) Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler 20:72–80. https://doi.org/10.1177/1352458513492245
doi: 10.1177/1352458513492245 pubmed: 23812283 pmcid: 4107776
Schlaeger R, Papinutto N, Panara V et al (2014) Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol 76:568–580. https://doi.org/10.1002/ana.24241
doi: 10.1002/ana.24241 pubmed: 25087920 pmcid: 5316412
Kearney H, Schneider T, Yiannakas MC et al (2015) Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 86:608–614. https://doi.org/10.1136/jnnp-2014-308241
doi: 10.1136/jnnp-2014-308241 pubmed: 25097217
Agosta F, Absinta M, Sormani MP et al (2007) In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain 130:2211–2219. https://doi.org/10.1093/brain/awm110
doi: 10.1093/brain/awm110 pubmed: 17535835
Lukas C, Knol DL, Sombekke MH et al (2015) Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2014-308021
doi: 10.1136/jnnp-2014-308021 pubmed: 25053773
Cohen AB, Neema M, Arora A et al (2012) The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis. J Neuroimaging 22:122–128. https://doi.org/10.1111/j.1552-6569.2011.00589.x
doi: 10.1111/j.1552-6569.2011.00589.x pubmed: 21447024
Preziosa P, Pagani E, Mesaros S et al (2017) Progression of regional atrophy in the left hemisphere contributes to clinical and cognitive deterioration in multiple sclerosis: A 5-year study. Hum Brain Mapp. https://doi.org/10.1002/hbm.23755
doi: 10.1002/hbm.23755 pubmed: 28792103 pmcid: 6866796
Bergsland N, Horakova D, Dwyer MG et al (2018) Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. NeuroImage Clin. https://doi.org/10.1016/j.nicl.2017.11.002
doi: 10.1016/j.nicl.2017.11.002 pubmed: 29527505 pmcid: 5842310
Eshaghi A, Prados F, Brownlee WJ et al (2018) Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 83:210–222. https://doi.org/10.1002/ana.25145
doi: 10.1002/ana.25145 pubmed: 29331092 pmcid: 5838522
Eshaghi A, Marinescu RV, Young AL et al (2018) Progression of regional grey matter atrophy in multiple sclerosis. Brain. https://doi.org/10.1093/brain/awy088
doi: 10.1093/brain/awy088 pubmed: 29741648 pmcid: 5995197
Tsagkas C, Chakravarty MM, Gaetano L et al (2020) Longitudinal patterns of cortical thinning in multiple sclerosis. Hum Brain Mapp. https://doi.org/10.1002/hbm.24940
doi: 10.1002/hbm.24940 pubmed: 32067281 pmcid: 7268070
Hidalgo de la Cruz M, Valsasina P, Gobbi C et al (2020) Longitudinal cortical thinning progression differs across multiple sclerosis phenotypes and is clinically relevant: A multicentre study. Mult Scler J. https://doi.org/10.1177/1352458520940548
doi: 10.1177/1352458520940548
Rocca MA, Valsasina P, Meani A et al (2019) Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. Neurology. https://doi.org/10.1212/WNL.0000000000008466
doi: 10.1212/WNL.0000000000008466 pubmed: 31611336 pmcid: 6345120
Liu Y, Duan Y, Huang J et al (2018) Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. Eur Radiol. https://doi.org/10.1007/s00330-017-4921-x
doi: 10.1007/s00330-017-4921-x pubmed: 30523454 pmcid: 6420610
Bonacchi R, Pagani E, Meani A et al (2020) Clinical relevance of multiparametric MRI assessment of cervical cord damage in multiple sclerosis. Radiology. https://doi.org/10.1148/radiol.2020200430
doi: 10.1148/radiol.2020200430 pubmed: 32573387
Zivadinov R, Bergsland N (2020) Cervical spinal cord lesions and atrophy versus brain measures in xxplaining physical disability in multiple sclerosis. Radiology 296:616–618. https://doi.org/10.1148/radiol.2020202304
doi: 10.1148/radiol.2020202304 pubmed: 32579091
Steenwijk MD, Geurts JJG, Daams M et al (2016) Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain. https://doi.org/10.1093/brain/awv337
doi: 10.1093/brain/awv337 pubmed: 26637488
Petracca M, Schiavi S, Battocchio M et al (2020) Streamline density and lesion volume reveal a postero–anterior gradient of corpus callosum damage in multiple sclerosis. Eur J Neurol. https://doi.org/10.1111/ene.14214
doi: 10.1111/ene.14214 pubmed: 33043560 pmcid: 7675416
Liu Y, Lukas C, Steenwijk MD et al (2016) Multicenter validation of mean upper cervical cord area measurements from head 3D T1-weighted MR imaging in patients with multiple sclerosis. Am J Neuroradiol. https://doi.org/10.3174/ajnr.A4635
doi: 10.3174/ajnr.A4635 pubmed: 28059707 pmcid: 7963866
Liu Z, Yaldizli Ö, Pardini M et al (2015) Cervical cord area measurement using volumetric brain magnetic resonance imaging in multiple sclerosis. Mult Scler Relat Disord. https://doi.org/10.1016/j.msard.2014.11.004
doi: 10.1016/j.msard.2014.11.004 pubmed: 25787053 pmcid: 4341972
Moccia M, Ruggieri S, Ianniello A et al (2019) Advances in spinal cord imaging in multiple sclerosis. Ther Adv Neurol Disord. https://doi.org/10.1177/1756286419840593
doi: 10.1177/1756286419840593 pubmed: 31040881 pmcid: 6477770
Lukas C, Prados F, Valsasina P, et al (2018) Quantification of spinal cord atrophy in MS: which software, which vertebral level, spinal cord or brain MRI? A multi-centric, longitudinal comparison of three different volumetric approaches. In: ECTRIMS Online Library
Preziosa P, Rocca MA, Riccitelli GC et al (2020) Effects of natalizumab and fingolimod on clinical, cognitive, and magnetic resonance imaging measures in multiple sclerosis. Neurotherapeutics 17:208–217. https://doi.org/10.1007/s13311-019-00781-w
doi: 10.1007/s13311-019-00781-w pubmed: 31452082

Auteurs

Serena Ruggieri (S)

Department of Human Neurosciences, Sapienza University, Rome, Italy.
Neuroimmunology Unit, IRCSS Fondazione Santa Lucia, Rome, Italy.

Maria Petracca (M)

Department of Human Neurosciences, Sapienza University, Rome, Italy. maria@petraccas.it.
Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy. maria@petraccas.it.

Laura De Giglio (L)

Department of Human Neurosciences, Sapienza University, Rome, Italy.
Neurology Unit, Medicine Department, San Filippo Neri Hospital, Rome, Italy.

Francesca De Luca (F)

PhD Program in Behavioral Neuroscience, Sapienza University, Rome, Italy.

Costanza Giannì (C)

Department of Radiology, IRCCS NEUROMED, Pozzilli, Italy.

Flavia Gurreri (F)

MS Center, Sant'Andrea Hospital, Rome, Italy.

Nikolaos Petsas (N)

Department of Radiology, IRCCS NEUROMED, Pozzilli, Italy.

Silvia Tommasin (S)

Department of Human Neurosciences, Sapienza University, Rome, Italy.

Carlo Pozzilli (C)

Department of Human Neurosciences, Sapienza University, Rome, Italy.
MS Center, Sant'Andrea Hospital, Rome, Italy.

Patrizia Pantano (P)

Department of Human Neurosciences, Sapienza University, Rome, Italy.
Department of Radiology, IRCCS NEUROMED, Pozzilli, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH